

Examination of the efficiency of ConHeal® sodium-hyaluronate containing eye drops in conjunctival and corneal epithelial injuries

Submission date 31/12/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 15/01/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/02/2023	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Dry eye complaints are one of the top reasons for visiting ophthalmologists. Conjunctivochalasis is a common dry eye disorder, which can cause an unstable tear film and ocular discomfort. It is characterised by excess folds of the conjunctiva between the globe of the eye and the eyelid margin and it usually requires surgery, although a conservative therapy would be highly desirable.

The aim of the study is to assess whether a preservative-free, inorganic salt-free unit-dose artificial tear, called Conheal®, can improve vision-related quality of life, even in the case of severe conjunctivochalasis which would traditionally require surgery.

Who can participate?

Adult patients with severe conjunctivochalasis.

What does the study involve?

Patients are given Conheal® eye drops four times a day for 3 months.

What are the possible benefits and risks of participating?

Not provided at time of registration.

Where is the study run from?

Department of Ophthalmology, Semmelweis University, Hungary

When is the study starting and how long is it expected to run for?

From August 2012 to November 2013

Who is funding the study?

"Four our Eyesight" Foundation (Budapest, Hungary).

Who is the main contact?

Dr Huba Kiss

Contact information

Type(s)

Scientific

Contact name

Dr Huba Kiss

Contact details

Mária str. 39.
Budapest
Hungary
1085

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Examination of the efficiency of ConHeal® sodium-hyaluronate containing eye drops in conjunctival and corneal epithelial injuries on patients with severe conjunctivochalasis measured by the Lid-Parallel CONjunctival Folds (LIPCOF) degree, tear film breakup time, corneal lissamine green staining and Ocular Surface Disease Index (OSDI) questionnaire score

Study objectives

Four times a day application of the artificial tear drops, Conheal® (provided by Pannonpharma Ltd., Pécsvárad, Hungary), containing isotonic glycerol and 0.015% hyaluronic acid in purified water for 1 and 3 months decreases the Lid-Parallel CONjunctival Folds (LIPCOF) degree characterizing severe conjunctivochalasis; increases tear film breakup time; reduces corneal lissamine green staining and decreases Ocular Surface Disease Index (OSDI) questionnaire score after 1 and 3 months of treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Hungarian Scientific and Research-Ethics Committee (<http://www.ett.hu/tukeb.htm>, tukeb@emmi.gov.hu), 07/12/2011, ref 21455-1/2011-EKU

Study design

Single-centre interventional trial

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Severe conjunctivochalasis, characterized by high LIPCOF degree, as both a reason and consequence of the dry eye disease.

Interventions

Patients receive the artificial tear drops, Conheal® (provided by Pannonpharma Ltd., Pécsvárad, Hungary), four times a day for 3 months. The drops contain isotonic glycerol and 0.015% hyaluronic acid in purified water

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Conheal® eye drops (provided by Pannonpharma Ltd., Pécsvárad, Hungary)

Primary outcome measure

Decrease in Lid-Parallel CONjunctival Folds (LIPCOF) degree characterizing severe conjunctivochalasis after 1 and 3 months of treatment.

Secondary outcome measures

1. Increase in tear film breakup time, reduction of corneal lissamine green staining, decrease of Ocular Surface Disease Index (OSDI) questionnaire score after 1 and 3 months of treatment.

Overall study start date

27/08/2012

Completion date

04/11/2013

Eligibility

Key inclusion criteria

1. Female and male patients older than 18
2. Severe conjunctivochalasis (having LId-Parallel CONjunctival Folds, LIPCOF degree 2 or higher)
3. Lissamine green staining of minimum grade 1 or higher on the Oxford Scheme grade, indicating a more advanced dry eye disease

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

20

Total final enrolment

20

Key exclusion criteria

1. Pregnancy or lactation
2. Pterygium
3. Prolonged treatment with eye drops with the exception of artificial tears
4. Active allergic keratoconjunctivitis
5. Current keratitis or conjunctivitis of infectious origin
6. Surgery affecting the eye surface
7. Eye injuries occurred within 3 months before starting the treatment

Date of first enrolment

27/08/2012

Date of final enrolment

24/07/2013

Locations**Countries of recruitment**

Hungary

Study participating centre

Department of Ophthalmology, Semmelweis University
Mária str. 39

Budapest
Hungary
1085

Sponsor information

Organisation

Semmelweis University, Department of Ophthalmology

Sponsor details

Mária str. 39.
Budapest
Hungary
1085

Sponsor type

University/education

Website

<http://semmelweis.hu/english/department-of-ophthalmology/>

ROR

<https://ror.org/01g9ty582>

Funder(s)

Funder type

Not defined

Funder Name

"Four our Eyesight" Foundation (Budapest, Hungary).

Results and Publications

Publication and dissemination plan

Preliminary data of the 1 month treatment were published in the Hungarian scientific journal Szemészet (Ophthalmology in Hungarian) https://www.researchgate.net/publication/262485247_Examination_of_conservative_treatment_possibility_of_conjunctivochalasis__A_preliminary_report

Full data of the 3-month study were published in PLoS ONE: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0132656>.

Intention to publish date

14/07/2015

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/07/2015		Yes	No
Protocol (other)			09/02/2023	No	No